Sandu [SANDUPHQ] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Sandu
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sandu wins in 7 metrics, Aarti Drugs wins in 13 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sandu | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.81 | 23.66 | Aarti Drugs |
| Price-to-Book Ratio | 1.05 | 3.26 | Sandu |
| Debt-to-Equity Ratio | 1.14 | 44.92 | Sandu |
| PEG Ratio | 0.79 | 0.37 | Aarti Drugs |
| EV/EBITDA | 14.56 | 17.07 | Sandu |
| Profit Margin (TTM) | 2.41% | 7.80% | Aarti Drugs |
| Operating Margin (TTM) | 2.08% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | 2.08% | 10.11% | Aarti Drugs |
| Return on Equity | 3.69% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 2.78% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $104,000 | $674.22M | Aarti Drugs |
| Dividend Yield | 1.61% | 0.22% | Sandu |
| 1-Year Return | -22.09% | -4.79% | Aarti Drugs |
| Price-to-Sales Ratio (TTM) | 0.67 | 1.84 | Sandu |
| Enterprise Value | $426.40M | $50.47B | Aarti Drugs |
| EV/Revenue Ratio | 0.64 | 2.08 | Sandu |
| Gross Profit Margin (TTM) | 47.10% | 36.77% | Sandu |
| Revenue per Share (TTM) | $69 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $1.66 | $20.63 | Aarti Drugs |
| Beta (Stock Volatility) | 0.17 | 0.12 | Aarti Drugs |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sandu vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sandu | 0.26% | -0.13% | -3.60% | -7.75% | -4.91% | -17.81% |
| Aarti Drugs | 0.73% | 4.61% | 0.24% | 1.59% | 41.06% | 7.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sandu | -22.09% | -33.31% | 42.40% | 36.12% | 219.17% | 98.20% |
| Aarti Drugs | -4.79% | -0.89% | -50.06% | 219.30% | 2,690.01% | 2,872.19% |
News Based Sentiment: Sandu vs Aarti Drugs
Sandu
News based Sentiment: NEGATIVE
September was a significantly negative month for Sandu Pharmaceuticals, characterized by a consistent decline in stock price, a shift in valuation to 'fair', and the first revenue contraction in three years. These developments, coupled with a notable stake sale and declining investor participation, create a concerning picture for investors and suggest a challenging period ahead for the company.
Aarti Drugs
News based Sentiment: POSITIVE
Aarti Drugs reported substantial profit growth in both Q1FY26 and FY2025, coupled with increased institutional interest from Mutual Funds. While shareholding changes and recent price volatility exist, the overall narrative points towards a strengthening investment case.
Performance & Financial Health Analysis: Sandu vs Aarti Drugs
| Metric | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹461.45M | ₹44.55B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,224 | 201,942 |
| 90 Day Avg. Volume | 1,326 | 187,563 |
| Last Close | ₹46.28 | ₹491.60 |
| 52 Week Range | ₹43.75 - ₹62.80 | ₹312.00 - ₹564.05 |
| % from 52W High | -26.31% | -12.84% |
| All-Time High | ₹86.00 (Apr 25, 2022) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -46.19% | -52.13% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.06% |
| Quarterly Earnings Growth | 0.34% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.08% |
| Operating Margin (TTM) | 0.02% | 0.10% |
| Return on Equity (TTM) | 0.04% | 0.12% |
| Debt to Equity (MRQ) | 1.14 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹43.77 | ₹149.84 |
| Cash per Share (MRQ) | ₹2.73 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹5.35M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹15.52M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.61% | 0.22% |
| Last 12-Month Dividend | ₹0.80 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Sandu vs Aarti Drugs
| Metric | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.81 | 23.66 |
| Forward P/E | N/A | 15.02 |
| PEG Ratio | 0.79 | 0.37 |
| Price to Sales (TTM) | 0.67 | 1.84 |
| Price to Book (MRQ) | 1.05 | 3.26 |
| Market Capitalization | ||
| Market Capitalization | ₹461.45M | ₹44.55B |
| Enterprise Value | ₹426.40M | ₹50.47B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.64 | 2.08 |
| Enterprise to EBITDA | 14.56 | 17.07 |
| Risk & Other Metrics | ||
| Beta | 0.17 | 0.12 |
| Book Value per Share (MRQ) | ₹43.77 | ₹149.84 |
Financial Statements Comparison: Sandu vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹166.99M | ₹5.91B |
| Cost of Goods Sold | ₹88.33M | ₹3.73B |
| Gross Profit | ₹78.66M | ₹2.17B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹3.48M | ₹593.60M |
| EBITDA | ₹5.43M | ₹743.90M |
| Pre-Tax Income | ₹3.39M | ₹511.10M |
| Income Tax | ₹1.15M | ₹-28.60M |
| Net Income (Profit) | ₹2.23M | ₹539.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹13.04M | ₹45.77M |
| Total Current Assets | ₹262.99M | ₹13.38B |
| Total Current Liabilities | ₹120.86M | ₹8.37B |
| Long-Term Debt | ₹4.19M | ₹2.86B |
| Total Shareholders Equity | ₹420.17M | ₹13.69B |
| Retained Earnings | ₹95.24M | ₹12.40B |
| Property, Plant & Equipment | ₹7.46M | ₹27.03M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,224 | 201,942 |
| Average Daily Volume (90 Day) | 1,326 | 187,563 |
| Shares Outstanding | 9.66M | 91.27M |
| Float Shares | 3.24M | 39.04M |
| % Held by Insiders | 0.66% | 0.60% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Sandu vs Aarti Drugs
| Metric | SANDUPHQ | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹0.80 | ₹1.00 |
| Last 12-Month Dividend Yield | 1.61% | 0.22% |
| 3-Year Avg Annual Dividend | ₹1.02 | ₹1.00 |
| 3-Year Avg Dividend Yield | 1.12% | 0.23% |
| 3-Year Total Dividends | ₹3.05 | ₹3.00 |
| Ex-Dividend Date | Sep 19, 2024 | Feb 04, 2025 |